A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

NCT00587067 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Hepatic Cancer

Interventions

DRUG: FLOXURIDINE

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]